COMP <GO>
TNGX vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
Tango Therapeutics Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: TNGX 3
— ABBV 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ABBV
LAST: $22.53 (+1.35%) • MKT CAP: $3.80B
roic
-28.90%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TNGX VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TNGX | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 70.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -28.90% | 29.00% | -57.90 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.68% | 3.47% | -7.15 | ABBV | /fcf-yield <GO> |
| Operating Margin | -60.00% | 24.60% | -84.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 6.90% | -66.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 48.30% | 8.60% | +39.70 | TNGX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.33 | +20.67 | TNGX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.0 | 65.1 | -19.10 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | 1.15 | -0.28 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.0x | 113.1x | -85.10 | TNGX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.80B | $513.86B | -$510.06B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TNGX REV | ABBV REV | TNGX GROSS % | ABBV GROSS % | TNGX FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $62.4M | $61.16B | — | 70.2% | -$139.9M | $17.82B |
| FY 2024 | $42.1M | $56.33B | — | 70.0% | -$132.3M | $17.83B |
| FY 2023 | $36.5M | $54.32B | — | — | -$119.6M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TNGX // BETA 0.87
ABBV // BETA 1.15